Introduction – Addressing Core Industry Needs and Solutions
Immuno-oncology researchers and vaccine developers face a critical preclinical challenge: traditional mouse models lack a functional human immune system, making them inadequate for studying human-specific immune responses, evaluating immunotherapies (checkpoint inhibitors, CAR-T cells, bispecific antibodies), or testing human vaccines. Humanized Immune System (HIS) mice are immunodeficient mice engrafted with human peripheral blood mononuclear cells (PBMCs) or hematopoietic stem cells (HSCs), enabling partial or full reconstruction of the human immune system. These models serve as powerful tools for studying human immune responses, infectious diseases, tumor immunology, vaccine development, and immunotherapy evaluation. HIS mice offer a unique in vivo platform to bridge preclinical research and human clinical applications. The three main engraftment models are Hu-PBMC (rapid, T-cell driven, risk of GVHD), Hu-HSC (long-term, multi-lineage engraftment, more human-like), and Hu-BLT (bone marrow-liver-thymus – most complete, most complex).
Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Humanized Immune System (HIS) Mice – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Humanized Immune System (HIS) Mice market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Humanized Immune System (HIS) Mice was estimated to be worth US$ 220 million in 2025 and is projected to reach US$ 360 million, growing at a CAGR of 7.4% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6094161/humanized-immune-system–his–mice
1. Core Market Drivers and Immuno-Oncology Demand
The global HIS mice market is projected to grow at 7.4% CAGR to US$360M by 2032, driven by immuno-oncology drug development (1,500+ active IO clinical trials), checkpoint inhibitor research (PD-1/PD-L1, CTLA-4, LAG-3, TIGIT), CAR-T cell therapy evaluation (solid tumors), and infectious disease modeling (HIV, EBV, dengue, SARS-CoV-2).
Recent data (Q4 2024–Q1 2026):
- Immuno-oncology market: $50B+ annually, driving demand for predictive preclinical models.
- Engraftment efficiency: Hu-PBMC (80-90% engraftment, 4-6 weeks), Hu-HSC (60-80%, 12-16 weeks), Hu-BLT (70-85%, 12-20 weeks).
- GVHD (graft-versus-host disease) risk: highest in Hu-PBMC (80-100% by week 8-10), limits study duration.
2. Segmentation: Engraftment Type and Application Verticals
- Hu-PBMC Mice (Peripheral Blood Mononuclear Cells) : Largest segment (50% market share). Fastest engraftment (2-4 weeks), high T-cell reconstitution, suitable for acute studies (4-8 weeks). Low cost ($100-300 per mouse). Best for: checkpoint inhibitor efficacy (PD-1, CTLA-4), T-cell engager evaluation. Limitation: GVHD limits study duration (<10 weeks). Vendors: Charles River, Taconic, Inotiv, Jackson Lab, Crown Bioscience, Champions Oncology.
- Hu-HSC Mice (Hematopoietic Stem Cells) : 35% share. Multi-lineage engraftment (T cells, B cells, NK cells, myeloid cells), long-term studies (6-12 months), more human-like immune system. Higher cost ($300-600 per mouse). Best for: vaccine studies, infectious disease (HIV, EBV), CAR-T cell persistence studies. Vendors: Jackson Lab, Taconic, GenOway, Oncodesign, Miltenyi Biotec, GemPharmatech, Shanghai Model Organisms.
- Hu-BLT Mice (Bone Marrow-Liver-Thymus) : 15% share (most complex, fastest-growing at 10% CAGR). Most complete human immune system (HLA-restricted T cells, mucosal immunity). Highest cost ($500-1,000 per mouse). Best for: HIV (mucosal transmission), genital tract infections, autoimmunity. Vendors: Jackson Lab, Taconic, BioDuro.
- By Application:
- Research Institutes: 55% share. Academic labs, non-profit research centers (NIH, CNRS, Max Planck). Focus on basic immunology, infectious disease, vaccine development.
- Pharmaceutical Companies: 45% share (fastest-growing at 9% CAGR). Drug discovery (lead optimization), preclinical efficacy studies (IO, vaccines, antivirals). Higher willingness-to-pay for validated models.
3. Industry Vertical Differentiation: Hu-PBMC vs. Hu-HSC vs. Hu-BLT
| Parameter | Hu-PBMC | Hu-HSC | Hu-BLT |
|---|---|---|---|
| Cell source | PBMCs (adult donor) | CD34+ HSCs (cord blood, fetal liver, mobilized peripheral blood) | Fetal liver CD34+ HSCs + fetal thymus |
| Engraftment time | 2-4 weeks | 12-16 weeks | 12-20 weeks |
| Study duration | 4-8 weeks (limited by GVHD) | 6-12 months | 6-12 months |
| T-cell reconstitution | High (human T cells) | Moderate | High |
| B-cell reconstitution | Low | Moderate | High |
| NK cell reconstitution | Low | Moderate | Moderate |
| Myeloid cells (macrophages, DCs) | Low | Moderate | Moderate |
| HLA restriction | No (donor T cells) | Limited | Yes (thymic education) |
| Mucosal immunity | No | Limited | Yes |
| GVHD risk | High (80-100% by week 8-10) | Low | Low |
| Cost per mouse | $100-300 | $300-600 | $500-1,000 |
| Best for | Checkpoint inhibitors, T-cell engagers (short-term) | Long-term studies, vaccines, infectious disease | HIV, mucosal immunity, autoimmunity |
Unlike Hu-PBMC (rapid, GVHD-limited), Hu-HSC and Hu-BLT offer long-term, multi-lineage human immune system reconstitution – essential for vaccine studies and chronic infection models (HIV, EBV).
4. User Case Studies and Technology Updates
Case – Charles River Laboratories : Market leader (25% share). 2025: Hu-PBMC (CDX, PDX models for IO). Price: $150-250 per mouse. For checkpoint inhibitor efficacy studies (pharma clients).
Case – Jackson Laboratory (JAX) : 2025: NSG-HSC (Hu-HSC on NSG background). Price: $400-600 per mouse. For long-term immuno-oncology studies, CAR-T persistence.
Case – Taconic Biosciences : 2025: Hu-CD34 (HSC-engrafted) and Hu-PBMC models. Price: $200-500. Strong in vaccine studies (HIV, COVID-19).
Case – GemPharmatech (China) : Domestic manufacturer. 2025: Hu-PBMC and Hu-HSC mice at $80-200 (50-60% below Western brands). Captured 35% of China market. 2025 volume: 50,000+ mice.
Technology Update (Q1 2026) :
- Next-gen NSG strains (NSG-SGM3, NSG-MHC double knockout) : Improved myeloid cell reconstitution (NSG-SGM3 expresses human IL-3, GM-CSF, SCF). Reduced GVHD (MHC knockout). Higher engraftment efficiency.
- Autologous HIS models: Patient-derived PBMCs or HSCs (personalized immuno-oncology models). For patient-specific CAR-T evaluation, neoantigen vaccine testing. Premium price ($1,000-5,000 per mouse).
- Humanized cytokine knock-in mice: Human IL-2, IL-7, IL-15, IL-21 knock-in (supports human immune cell development, persistence). Improved HIS mouse performance.
5. Exclusive Industry Insight: Model Selection and TCO
Our analysis reveals that model selection depends on study duration and immune readout requirements – Hu-PBMC for acute IO efficacy (<8 weeks), Hu-HSC/BLT for chronic studies (>12 weeks).
Proprietary model selection framework:
| Study type | Recommended model | Duration | Key readouts | Cost per mouse |
|---|---|---|---|---|
| Checkpoint inhibitor efficacy (PD-1, CTLA-4) | Hu-PBMC | 4-6 weeks | Tumor volume, T-cell infiltration, IFN-γ | $150-250 |
| CAR-T cell therapy (solid tumors) | Hu-HSC (NSG) | 8-12 weeks | CAR-T persistence, tumor regression, cytokines | $400-600 |
| Bispecific T-cell engager (BiTE) | Hu-PBMC | 3-5 weeks | T-cell activation, tumor killing | $150-250 |
| Cancer vaccine (neoantigen) | Hu-HSC or Hu-BLT | 12-20 weeks | T-cell response (tetramer, ELISpot), tumor protection | $400-800 |
| HIV (latency, cure) | Hu-BLT | 16-24 weeks | Viral load, CD4 count, reservoir size | $600-1,000 |
| SARS-CoV-2 / influenza vaccine | Hu-HSC | 12-16 weeks | Antibody titers, T-cell response, viral challenge | $300-600 |
TCO analysis (immuno-oncology study, 10 mice/group, 5 groups, 1 experiment) :
| Model | Cost per mouse | Total mice (10/group x 5 = 50) | Total cost | Study duration | Labor cost (@$100/hour) | Total TCO |
|---|---|---|---|---|---|---|
| Hu-PBMC | $200 | 50 | $10,000 | 6 weeks (240 hours) | $24,000 | $34,000 |
| Hu-HSC | $500 | 50 | $25,000 | 12 weeks (480 hours) | $48,000 | $73,000 |
| Hu-BLT | $800 | 50 | $40,000 | 16 weeks (640 hours) | $64,000 | $104,000 |
Key insight: Hu-PBMC has lowest TCO for short-term studies. Hu-HSC/BLT justified for chronic studies where Hu-PBMC fails (GVHD limits duration to <8 weeks).
Regional Dynamics:
- North America (45% market share): Largest market. US (Charles River, Taconic, Jackson Lab, Inotiv, Champions Oncology, BioDuro – high pharma R&D spending). Strong IO focus.
- Europe (30% market share): UK, Germany, France. Janvier, GenOway, Oncodesign Services, Miltenyi Biotec. Strong academic research base.
- Asia-Pacific (20% share, fastest-growing at 10% CAGR): China (GemPharmatech, Shanghai Model Organisms, Biocytogen – domestic manufacturing, 40-60% discount). Japan, South Korea.
- Rest of World (5%): Latin America, Middle East.
Market Outlook 2026–2032
The global HIS mice market is projected to grow at 7.4% CAGR, reaching US$360M by 2032. Hu-PBMC remains largest segment (50% share) for acute IO studies. Hu-HSC and Hu-BLT fastest-growing (9-10% CAGR) for long-term studies (vaccines, infectious disease, CAR-T). Next-gen NSG strains (NSG-SGM3, MHC knockout) improve myeloid reconstitution, reduce GVHD. Autologous HIS models (patient-derived) for personalized immuno-oncology (premium segment). Asia-Pacific fastest-growing (10% CAGR) driven by China (GemPharmatech, Shanghai Model Organisms, Biocytogen).
Success requires mastering three capabilities: (1) engraftment efficiency (80-90% for PBMC, 60-80% for HSC), (2) multi-lineage reconstitution (T, B, NK, myeloid cells), and (3) GVHD mitigation (for Hu-PBMC, use NSG-MHC knockout). Vendors with comprehensive HIS portfolios (Charles River, Taconic, Jackson Lab) and next-gen NSG strains will capture leadership; domestic manufacturers (GemPharmatech, Shanghai Model Organisms) lead price-sensitive Asia-Pacific market.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
